Analyst Says Axovant's Bull Case Is Effectively Over
September 27, 2017 at 13:32 PM EDT
Following the failure of Axovant Sciences Ltd (NASDAQ: AXON)'s late-stage MINDSET study, which evaluated its Alzheimer's treatment ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.